CoSign Electronic Signatures delivered with DataLabs Site Manager 2.0
CoSign electronic signature reduces the time and cost of clinical trials, helping sponsors and CROs comply with the FDA's 21 CFR Part 11 and GxP regulations.
PHILADELPHIA-June 19, 2006-Algorithmic Research (ARX), a leading worldwide provider of electronic signatures and data security solutions, announced from the Drug Information Association (DIA) 42nd Annual Conference an agreement to integrate its CoSign electronic signature solution with DataLabs' Site Manager 2.0 collaboration software.
This integrated solution enables sponsors and CROS to electronically sign documents, forms and agreements using standard electronic signatures, which reduces the time and cost to clinical trials while complying with the FDA's 21 CFR Part 11 and GxP regulations.
DataLabs will be at booth #1829 at the DIA Annual Conference
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
